Evidence map›Paper›PMID 35345381›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats.

Sri Susilowati, Hermawan Istiadi, Suhartono Suhartono, Yan Wisnu Prajoko, Ignatius Riwanto, Neni Susilaningsih, Catharina Suharti

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sri SusilowatiDoctoral Program of Medical and Health Sciences, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Hermawan IstiadiDepartment of Anatomical Pathology, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Suhartono SuhartonoDepartment of Environmental Health, Public Health Faculty, Diponegoro University, Semarang, Indonesia.
Yan Wisnu PrajokoDepartment of Surgical Oncology, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.ORCID 0000-0003-2659-9923
Ignatius RiwantoDepartment of Surgery, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Neni SusilaningsihDepartment of Anatomy Histology, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Catharina SuhartiDepartment of Medicine, Hematology-Medical Oncology Division, School of Medicine, Diponegoro University, Semarang, Indonesia.
Diponegoro University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to determine the role of beetroot extract in overcoming the chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide (NAC) regimens with a target immune response in the tumour microenvironment at the pre-clinical stage.

methodsThis study was conducted on rats with 7,12-Dimethyl Benz (α) Anthracene (DMBA) induced mammary adenocarcinoma. Adriamycin Cyclophosphamide was given in 4 cycles, whereas beetroot extract was administered three times each cycle. Observations of CD8 T cells and Myeloid Derivative Suppressive Cells (MDSC) expression levels and pathological responses were carried out on tumour tissue taken at the end of the observation.

resultsSupplementation of beetroot extract to NAC could significantly increase CD8 T cells and decrease MDSC in the tumour microenvironment. The addition of beetroot extract gave a better pathological response.

conclusionBeetroot extract enhances the immune response in the tumor microenvironment so that it has the potential to overcome chemoresistance in NAC.<br />.

Indexed as

AdenocarcinomaBreast NeoplasmsAnimalsCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleHumansImmunityNeoadjuvant TherapyPlant ExtractsRatsTumor MicroenvironmentCyclophosphamideDoxorubicinPlant ExtractsBeetrootCD8 T cellsChemoresistanceMyeloid Derivative Suppressive CellsNeoadjuvant Adriamycin-Cyclophosphamide

Identifiers

PMID35345381
PMCPMC9360944
OpenAlexW4221015644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.